| Literature DB >> 11087565 |
Q Han1, C Dominguez, P F Stouten, J M Park, D E Duffy, R A Galemmo, K A Rossi, R S Alexander, A M Smallwood, P C Wong, M M Wright, J M Luettgen, R M Knabb, R R Wexler.
Abstract
Thrombotic diseases are a major cause of death and morbidity. Factor Xa (fXa) plays a vital role in the regulation of normal homeostasis and abnormal intravascular thrombus development in the blood coagulation cascade. A novel series of fXa inhibitors incorporating an amidino 6,5-fused bicyclic moiety at the P1 position has been designed and synthesized based on molecular modeling studies. Structure-activity relationship (SAR) studies have led to selective subnanomolar fXa inhibitors. The most potent fXa inhibitor in this series (72, SE170) has a potent inhibition constant (K(i) = 0.3 nM), is 350-fold selective for fXa over trypsin, and also shows good in vivo efficacy in a rabbit arterio-venous thrombosis model (ID(50) = 0.14 micromol/kg/h). An X-ray crystal structure of 72 complexed to bovine trypsin was completed, and a binding mode of 72 with fXa has been proposed based on modeling with human des-Gla-fXa.Entities:
Mesh:
Substances:
Year: 2000 PMID: 11087565 DOI: 10.1021/jm000113t
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446